

RNS Number : 3335K
Ananda Developments PLC
21 December 2022

21 December 2022

ANANDA DEVELOPMENTS PLC

("Ananda" or the "Company")

NHS MEDICAL CANNABIS REGISTRY

The directors note the recent announcement by the NHS encouraging the use of its medical cannabis registry and welcomes this move to increase the awareness, use and potential of cannabis medicines for UK patients.

<https://www.england.nhs.uk/long-read/cannabis-based-products-for-medicinal-use-patient-registry/>

-Ends-

ANANDA DEVELOPMENTS PLC +44 (0)7463 686 497

Chief Executive Officer

Melissa Sturgess

Investor Relations

Jeremy Sturgess-Smith

PETERHOUSE CAPITAL LIMITED +44 (0)20 7469 0930

Corporate Finance

Mark Anwyl

Corporate Broking

Lucy Williams

Duncan Vasey

About Ananda Developments

Ananda is an AQSE-listed medical cannabis company creating UK-based operations to grow and provide carbon zero, consistent, medical cannabis for the UK and international markets.

The UK medical cannabis market is predicted to be worth £450m by 2025 and the European market is predicted to be worth USD4.2bn by 2027.

For more information, please visit: <https://anandadevelopments.com/>

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).